Aurinia Pharmaceuticals Inc (AUPH) concluded trading on Thursday at a closing price of $7.55, with 4.49 million shares of worth about $33.91 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 12.52% during that period and on February 27, 2025 the price saw a loss of about -5.03%. Currently the company’s common shares owned by public are about 143.11M shares, out of which, 128.78M shares are available for trading.
Stock saw a price change of -3.58% in past 5 days and over the past one month there was a price change of -8.37%. Year-to-date (YTD), AUPH shares are showing a performance of -15.92% which increased to 25.83% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.71 but also hit the highest price of $10.67 during that period. The average intraday trading volume for Aurinia Pharmaceuticals Inc shares is 1.31 million. The stock is currently trading -4.73% below its 20-day simple moving average (SMA20), while that difference is down -8.85% for SMA50 and it goes to 7.26% higher than SMA200.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) currently have 143.11M outstanding shares and institutions hold larger chunk of about 39.38% of that.
The stock has a current market capitalization of $1.08B and its 3Y-monthly beta is at 1.27. It has posted earnings per share of -$0.16 in the same period. It has Quick Ratio of 5.11 while making debt-to-equity ratio of 0.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AUPH, volatility over the week remained 6.10% while standing at 4.14% over the month.
Stock’s fiscal year EPS is expected to rise by 1062.50% while it is estimated to increase by 30.11% in next year. EPS is likely to grow at an annualized rate of 178.06% for next 5-years, compared to annual growth of 6.35% made by the stock over the past 5-years.
Coverage by Cantor Fitzgerald stated Aurinia Pharmaceuticals Inc (AUPH) stock as an Overweight in their note to investors on May 05, 2022, suggesting a price target of $25 for the stock. On December 10, 2021, Oppenheimer Upgrade their recommendations, while on October 28, 2021, Oppenheimer Downgrade their ratings for the stock with a price target of $32. Stock get a Buy rating from H.C. Wainwright on January 25, 2021.
